1 Product Definition
1.1 Inclusion and Exclusion

2 Research Methodology
2.1 Primary Data Sources
2.2 Secondary Data Sources
2.3 Market Estimation Model
2.4 Selection Criteria for Company Profiles

3 Global Cell and Gene Therapy Market: Global Prospective
3.1 Introduction
3.2 Cell and Gene Therapy and Their Clinical Importance
3.3 Cell and Gene Therapy Development and Commercialization Landscape
3.4 Global Cell and Gene Therapy Market Size, 2020-2027
3.5 Role of Regulatory Bodies and Consortium in Cell and Gene Therapy
3.6 Reimbursement and Market Access
3.6.1 Reimbursement Scenario of Cell and Gene Therapy Market, by Country
3.6.1.1 U.S.
3.6.1.2 EU 5
3.6.1.2.1 France
3.6.1.2.2 Germany
3.6.1.2.3 Italy
3.6.1.2.4 Spain
3.6.1.2.5 U.K.
3.7 Key Companies in Cell and Gene Therapy Market and their Contributions

4 Market Overview
4.1 Cell and Gene Therapy Industry
4.2 Key Successful Cell and Gene Therapy Commercialization
4.2.1 Regional Addressable Market and Growth Potential
4.3 North America
4.4 Europe
4.5 Asia-Pacific
4.6 Latin America
4.7 Rest-of-the-World

5 Impact of COVID-19 Pandemic on Global Cell and Gene Therapy Market
5.1 Disruption of Cell and Gene Therapy Market Due to COVID-19
5.2 COVID-19 Affecting Supply Chain of Cell and Gene Therapy Market
5.3 Interruption in Research and Clinical Development and Commercial Operation
5.3.1 Research and Clinical Development
5.3.2 Commercial Operation and Access
5.4 Navigating Crisis Recovery and Looking to the Future

6 Global Cell and Gene Therapy Market: Industry Analysis
6.1 Legal and Regulatory Framework and Requirements
6.1.1 Overview of Regulatory Pathway for Cell and Gene Therapy
6.1.1.1 Fast Track Designation:
6.1.1.2 Breakthrough Therapy:
6.1.1.3 Accelerated Approval:
6.1.1.4 Priority Review:
6.1.1.5 Regenerative Medicine Advanced Therapy Designation:
6.1.2 Expedited Designation Vs. Traditional Approval Timelines:
6.1.3 Regulatory Challenges
6.1.4 Successful Regulatory Strategies

7 Patent Landscape

8 Cell and Gene Therapy Manufacturing
8.1 Viral Vector Manufacturing
8.1.1 Retrovirus
8.1.2 Lentivirus
8.1.3 AAV
8.1.4 Adenovirus
8.2 Upstream Manufacturing
8.2.1 Cost Consideration and Timelines
8.2.2 Process Design and Regulatory Burdens
8.2.3 Other Considerations
8.3 Downstream Manufacturing
8.3.1 Cost Considerations and Timelines
8.3.2 Challenges in Downstream
8.3.3 Scale-Up of Downstream from Research to Clinical Manufacturing
8.4 Non-Viral Vector Manufacturing
8.4.1 Non-Viral, Plasmid-Free Manufacturing
8.4.2 Plasmid
8.4.3 Naked DNA
8.4.4 Physical-Mediated Methods
8.5 Cell and Gene Therapy Manufacturing Capacity, by Company

9 Global Cell and Gene Therapy Market: Market Dynamics
9.1 Overview
9.2 Market Drivers
9.2.1 Increasing Incidences of Cancer and Other Chronic Diseases
9.2.2 High Number of Rare Diseases Across Globe
9.2.3 Rising Number of Clinical Trials
9.2.4 Increasing Funding and Investments in Cell and Gene Therapy Market
9.2.5 Favorable Regulatory Environment for Cell and Gene Therapy Products
9.3 Market Restrains
9.3.1 Lack of Reliable Vector Production for Cell and Gene Therapy
9.3.2 Complex Manufacturing and Distribution Setup
9.3.3 Tedious Process of Therapeutic Commercialization
9.4 Market Opportunities
9.4.1 Drug Approvals and Strong Pipeline of Cell and Gene Therapies
9.4.2 Increasing Number of Mergers and Acquisitions within the Cell and Gene Industry

10 Global Cell and Gene Therapy Market: Competitive Landscape
10.1 Key Strategies and Development
10.1.1 Product Offerings and Approvals
10.2 Synergistic Activities
10.3 Funding and Business Expansions
10.4 Mergers and Acquisitions
10.5 Market Share Analysis
10.6 Growth-Share Analysis (by Company), 2020

11 Global Cell and Gene Therapy Market (by Product)
11.1 Therapeutic Market
11.1.1 Yescarta
11.1.2 Provenge
11.1.3 Luxturna
11.1.4 Kymriah
11.1.5 Imlygic
11.1.6 Gintuit
11.1.7 MACI
11.1.8 Gendicine
11.1.9 Oncorine
11.1.10 Neovasculgen
11.1.11 Strimvelis
11.1.12 Invossa
11.1.13 Zolgensma
11.1.14 Tecartus
11.1.15 Liso-Cel
11.1.16 Zyntelego
11.1.17 Others
11.2 Pipeline Analysis
11.2.1 Phase 1
11.2.2 Phase 2
11.2.3 Phase 3
11.2.3.1 SPK-8011
11.2.3.2 OTL-103
11.2.3.3 OTL-200
11.2.3.4 OTL-101
11.2.3.5 VM202
11.2.3.6 GS010
11.2.3.7 bb2121
11.2.3.8 PTC-AADC
11.2.4 Pipeline Analysis – CAR-T Focused
11.2.5 Pipeline Analysis – CAR-NK Focused

12 Global Cell and Gene Therapy Market (by Therapeutic Class)
12.1 Overview
12.2 Rare Diseases
12.3 Oncology
12.4 Hematology
12.5 Cardiovascular
12.6 Ophthalmology
12.7 Neurology
12.8 Other Therapeutic Classes

13 Global Cell and Gene Therapy Market (by Region)
13.1 Overview
13.2 North America
13.2.1 U.S.
13.2.1.1 Approved Products
13.2.1.2 Competitive Landscape
13.2.1.3 Market Size and Forecast
13.2.1.4 Key Developments
13.2.2 Canada
13.2.2.1 Approved Products
13.2.2.2 Market Size and Forecast
13.2.2.3 Key Developments
13.3 Europe
13.3.1 Europe Cell and Gene Therapy Market Dynamics
13.3.2 Germany
13.3.2.1 Approved Products
13.3.2.2 Market Size and Forecast
13.3.2.3 Key Developments
13.3.3 France
13.3.3.1 Approved Products
13.3.3.2 Market Size and Forecast
13.3.3.3 Key Developments
13.3.3.4 Competitive Landscape
13.3.4 U.K.
13.3.4.1 Approved Products
13.3.4.2 Market Size and Forecast
13.3.4.3 Competitive Landscape
13.3.5 Italy
13.3.5.1 Approved Products
13.3.5.2 Market Size and Forecast
13.3.5.3 Key Developments
13.3.6 Spain
13.3.6.1 Approved Products
13.3.6.2 Market Size and Forecast
13.3.6.3 Key Developments
13.3.6.4 Competitive Landscape
13.3.7 The Netherlands
13.3.7.1 Approved Products
13.3.7.2 Market Size and Forecast
13.3.7.3 Key Developments
13.3.7.4 Competitive Landscape
13.3.8 Russia
13.3.8.1 Approved Products
13.3.8.2 Market Size and Forecast
13.3.8.3 Competitive Landscape
13.3.9 Rest-of-Europe
13.3.9.1 Market Size and Forecast
13.3.9.2 Key Developments
13.4 Asia-Pacific (APAC)
13.4.1 Japan
13.4.1.1 Approved Products
13.4.1.2 Market Size and Forecast
13.4.1.3 Key Developments
13.4.1.4 Competitive Landscape
13.4.2 China
13.4.2.1 Approved Products
13.4.2.2 Market Size and Forecast
13.4.2.3 Key Developments
13.4.2.4 Competitive Landscape
13.4.3 Australia
13.4.3.1 Approved Products
13.4.3.2 Market Size and Forecast
13.4.3.3 Key Developments
13.4.4 South Korea
13.4.4.1 Approved Products
13.4.4.2 Market Size and Forecast
13.4.4.3 Key Developments
13.4.4.4 Competitive Landscape
13.4.5 India
13.4.5.1 Approved Products
13.4.5.2 Market Size and Forecast
13.4.5.3 Competitive Landscape
13.4.6 Singapore
13.4.6.1 Approved Products
13.4.6.2 Market Size and Forecast
13.4.6.3 Key Developments
13.4.7 Rest-of-Asia-Pacific
13.4.7.1 Market Size and Forecast
13.4.7.2 Key Developments
13.5 Latin America
13.5.1 Brazil
13.5.1.1 Market Size and Forecast
13.5.2 Mexico
13.5.2.1 Market Size and Forecast
13.5.3 Rest-of-Latin America (RoLA)
13.5.3.1 Market Size and Forecast
13.6 Rest-of-World
13.6.1 Market Size and Forecast

14 Company Profile
14.1 Amgen Inc.
14.1.1 Company Overview
14.1.2 Role of Amgen Inc. in the Global Cell and Gene Therapy Market
14.1.3 Financials
14.1.4 Key Insights About Financial Health of the Company
14.1.5 SWOT Analysis
14.2 bluebird bio, Inc.
14.2.1 Company Overview
14.2.2 Role of bluebird bio, Inc. in the Global Cell and Gene Therapy Market
14.2.3 Financials
14.2.4 Key Insights About Financial Health of the Company
14.2.5 SWOT Analysis
14.3 Dendreon Pharmaceuticals LLC.
14.3.1 Company Overview
14.3.2 Role of Dendreon Pharmaceuticals LLC. in the Global Cell and Gene Therapy Market
14.3.3 SWOT Analysis
14.4 Castle Creek Pharmaceutical Holdings
14.4.1 Company Overview
14.4.2 Role of Castle Creek Pharmaceutical Holdings in the Global Cell and Gene Therapy Market
14.4.3 SWOT Analysis
14.5 Human Stem Cells Institute
14.5.1 Company Overview
14.5.2 Role of Human Stem Global Cell and Gene Therapy Cell Market
14.5.3 SWOT Analysis
14.6 Kite Pharma, Inc.
14.6.1 Company Overview
14.6.2 Role of Kite Pharma, Inc. in the Global Cell and Gene Therapy Market
14.6.3 Financials
14.6.4 Key Insights About Financial Health of the Company
14.6.5 SWOT Analysis
14.7 Kolon TissueGene, Inc.
14.7.1 Company Overview
14.7.2 Role of Kolon TissueGene, Inc. in the Global Cell and Gene Therapy Market
14.7.3 SWOT Analysis
14.8 Novartis AG
14.8.1 Company Overview
14.8.2 Role of Novartis AG in the Global Cell and Gene Therapy Market
14.8.3 Financials
14.8.4 Key Insights About Financial Health of the Company
14.8.5 SWOT Analysis
14.9 Orchard Therapeutics plc.
14.9.1 Company Overview
14.9.2 Role of Orchard Therapeutics plc. in the Global Cell and Gene Therapy Market
14.9.3 Financials
14.9.4 SWOT Analysis
14.10 Organogenesis Holdings Inc.
14.10.1 Company Overview
14.10.2 Role of Organogenesis Holdings Inc. in the Global Cell and Gene Therapy Market
14.10.3 Financials
14.10.4 Key Insights About Financial Health of the Company
14.10.5 SWOT Analysis
14.11 Pfizer, Inc.
14.11.1 Company Overview
14.11.2 Role of Pfizer, Inc. in the Global Cell and Gene Therapy Market
14.11.3 Financials
14.11.4 Key Insights About Financial Health of the Company
14.11.5 SWOT Analysis
14.12 RENOVA THERAPEUTICS
14.12.1 Company Overview
14.12.2 Role of RENOVA THERAPEUTICS in the Global Cell and Gene Therapy Market
14.12.3 SWOT Analysis
14.13 Shanghai Sunway Biotech Co., Ltd.,
14.13.1 Company Overview
14.13.2 Role of Shanghai Sunway Biotech Co., Ltd., in the Global Cell and Gene Therapy Market
14.13.3 SWOT Analysis
14.14 Sibiono GeneTech Co. Ltd.,
14.14.1 Company Overview
14.14.2 Role of Sibiono GeneTech Co. Ltd., in the Global Cell and Gene Therapy
14.14.3 SWOT Analysis
14.15 Spark Therapeutics, Inc.
14.15.1 Company Overview
14.15.2 Role of Spark Therapeutics, Inc. in the Global Cell and Gene Test Market
14.15.3 Financials
14.15.4 Key Insights About Financial Health of the Company
14.15.5 SWOT Analysis
14.16 Vericel Corporation
14.16.1 Company Overview
14.16.2 Role of Vericel Corporation in the Global Cell and Gene Therapy Market
14.16.3 Financials
14.16.4 Key Insights About Financial Health of the Company
14.16.5 SWOT Analysis